On November 12, WUXI APPTEC posted an Intraday Rise of 3.15% in Regular Trading, trading at HK$202.4 with turnover of HK$543 million.
The move followed continued positive sell-side reactions after the company was removed from the US Department of Defense 1260H list, with major institutions maintaining positive ratings and framing the development as a partial easing of geopolitical risk.
Recent coverage indicated the delisting was made after the Pentagon decided to comply with a court order tied to a preliminary injunction. JPMorgan maintained an Overweight rating with a HK$233 target price, while Goldman kept a Buy rating and HK$251 target. Earlier reports also noted strong operating momentum, including first-nine-month revenue of RMB45.54 billion, continuing operations growth of 46.3%, and backlog of RMB76.74 billion. Even so, market commentary said investors are still watching follow-on regulatory variables, including BIOSECURE-related frameworks and other US lists, meaning the latest rebound reflects risk relief rather than a full removal of cross-border policy uncertainty.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments